logo
  • ABOUT US
    • Our Story
    • Message From Our CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • OUR SCIENCE
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate With Us
    • Meet with TG Medical
  • OUR PRODUCTS
  • OUR PIPELINE
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG 1801
  • OUR PUBLICATIONS
  • OUR TRIALS
    • Trial Information
    • Expanded Access Policy
  • INVESTORS & MEDIA
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • Sec Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Leadership Team
    • Corporate Governance
    • Faqs
logo
Mobile Menu Mobile Close
  • ABOUT US
    • Our Story
    • Message From Our CEO
    • Leadership Team
    • Board Members
    • Guiding Principles
    • Join Us
  • OUR SCIENCE
    • Our Approach
    • Our Focus
      • MZL/FL
      • CLL
      • MS
    • Collaborate With Us
    • Meet with TG Medical
  • OUR PRODUCTS
  • OUR PIPELINE
    • Overview
    • Umbralisib
    • Ublituximab
    • TG-1501
    • TG-1701
    • TG 1801
  • OUR PUBLICATIONS
  • OUR TRIALS
    • Trial Information
    • Expanded Access Policy
  • INVESTORS & MEDIA
    • Press Releases
    • Stock Information
      • Historic Stock Lookup
    • Sec Filings & Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Events
    • IR & Media Contact
    • Leadership Team
    • Corporate Governance
    • Faqs
  • Search

    LEARN MORE ABOUT OUR FEARLESS PURSUIT

    LATEST NEWS

    TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

    Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B.

    Read More >

    GET INVESTOR
    INFORMATION

    HEAR OUR
    STORY

    READ OUR
    PUBLICATIONS

    EXPLORE OUR
    PIPELINE

    JOIN OUR
    TEAM

    HEAR OUR
    STORY

    EXPLORE OUR
    PIPELINE

    READ OUR
    PUBLICATIONS

    JOIN OUR
    TEAM

    GET INVESTOR
    INFORMATION

    LATEST NEWS

    TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

    Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B.

    Read More >

    GET INVESTOR
    INFORMATION

    HEAR OUR
    STORY

    READ OUR
    PUBLICATIONS

    EXPLORE OUR
    PIPELINE

    JOIN OUR
    TEAM

    logo

    ©2022 TG Therapeutics, Inc. All rights reserved. 

    • Join Us
    • Contact Us
    • Expanded Access Policy
    • PRIVACY POLICY
    • Terms of Use

    You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

    CONTINUE Return to tgtherapeutics.com